There's not a trial update as yet and so there is no additional info on those additional patients enrolled in the trial. The footnote by the 24 April 2024 date clearly notes those additional patients are part of an enrolment update and have had at least their first scan. 'Evaluable' is not the same as 'evaluated'.
So let's be clear, you're not here to warn us.
I actually lol'd when you claimed Cretostimogene hasn't been able to achieve an approval in 12 years. Where's Bisantrene at? Good grief man.
Your main guy said in his HotCopper advertorial that it was "and old drug that was <cough> very successful". But then it was shelved. Use your best Borat impersonation when you say out loud "very successful to reach back of shelf".
The cough was real too btw. Yikes.
Dingo, go join them there.
Ann: Imugene Presentation to Bell Potter Conference, page-37
-
- There are more pages in this discussion • 123 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.9¢ |
Change
0.005(9.26%) |
Mkt cap ! $433.6M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.9¢ | 5.4¢ | $1.489M | 25.99M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 35252 | 5.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.0¢ | 1753430 | 24 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |